Lorusso D, Xiang Y, Hasegawa K, Scambia G, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
PMID: 38521086